Topical TYK2 inhibitor ameliorates psoriasis‐like dermatitis via the AKT‐SP1‐NGFR‐AP1 pathway in keratinocytes
Topical TYK2 inhibitor alleviates psoriasis-like dermatitis. Topical TYK2 inhibitor reduces psoriasis progression through restraining the inflammatory responses of keratinocytes. The inhibition of TYK2 regulates the inflammatory response of keratinocytes through AKT-SP1-NGFR-AP1 pathway.
Authors
- Mingzhu Yin (ORCID: https://orcid.org/0000-0002-6964-7131)
- Wangqing Chen (ORCID: https://orcid.org/0000-0002-0933-4694)
- Xiang Chen (ORCID: https://orcid.org/0000-0002-6058-0049)
- Rundong Jiang (ORCID: https://orcid.org/0000-0002-9217-0749)
- Zhiqin Fang
- Yutong Wang (ORCID: https://orcid.org/0000-0002-1612-1873)
Institutions
- Central South University (CN)
- Chongqing University (CN)
- University of Michigan (US)
- Hunan Cancer Hospital (CN)
- Xiangya Hospital Central South University (CN)
- Chongqing Three Gorges University (CN)
Publication Details
- Journal
- Clinical and Translational Medicine
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1002/ctm2.70256
- Citations
- 3
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 2.39
Funders
- Natural Science Foundation of Hunan Province